Ipsen (FR:IPN)
:IPN
Want to see FR:IPN full AI Analyst Report?
IPN Stock Chart & Stats
€161.80
€0.40(0.34%)
At close: 4:00 PM EST
€161.80
€0.40(0.34%)
Day’s Range― - ―
52-Week Range€100.20 - €173.50
Previous CloseN/A
Volume2.80K
Average Volume (3M)64.26K
Market Cap
€12.99B
Enterprise Value€12.48B
Total Cash (Recent Filing)€1.53B
Total Debt (Recent Filing)€1.05B
Price to Earnings (P/E)29.2
Beta0.49
Next Earnings
Jul 30, 2026EPS Estimate
6.07Next Dividend Ex-DateN/A
Dividend Yield1.17%
Share Statistics
EPS (TTM)5.36
Shares Outstanding83,814,530
10 Day Avg. Volume52,964
30 Day Avg. Volume64,259
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€155.67Price Target Upside-3.79% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)12.96
Revenue Forecast (FY)€4.28B
Bulls Say, Bears Say
Bulls Say
Specialty-focused PortfolioIpsen's focus on oncology, rare diseases and neuroscience creates durable competitive barriers and pricing power. Specialization supports higher margins, targeted R&D, and resilient demand across diversified therapeutic areas and international channels over the medium term.
Multi-year Revenue Growth & ProfitabilityConsistent revenue expansion with sustained EBITDA margins near 30% shows structural operating strength. That profitability supports reinvestment in R&D and commercial rollout, enabling continued product development and scalable commercialization over the next several months.
Improved Cash Generation In 2025A ~€1.03B FCF and FCF/net income ~0.91 in 2025 indicates higher earnings quality and internal funding capacity. Strong cash conversion provides durable flexibility to fund R&D, milestone payments, and debt servicing without heavy reliance on external financing.
Bears Say
Margin Compression Since 2021–2023A material drop in net margin from prior years suggests structural cost, pricing or mix pressures. Prolonged margin erosion can reduce free cash flow and ROE, limiting capacity for R&D, commercial investment and shareholder returns across the medium term.
Sharp Step-up In Total Debt In 2025An abrupt increase in total debt reduces financial flexibility even if leverage remains moderate (debt/equity ~0.24). Higher indebtedness raises interest and refinancing risk and can constrain capital allocation if cash flows slip in the coming months.
Historically Volatile Free Cash Flow ConversionInconsistent FCF generation, with a notable weak 2024, signals execution and working-capital variability. That volatility complicates planning for R&D, milestone payments and M&A, increasing liquidity and operational risk over the 2–6 month horizon.
IPN FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest stock price was €100.20 and its highest was €173.50 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is €12.99B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Jul 30, 2026 which is in 47 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Feb 12, 2026. The company reported €6.02 earnings per share for the quarter, beating the consensus estimate of €5.527 by €0.493.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Overvalued.
Does Ipsen pay dividends?
Ipsen pays a Annually dividend of €1.6 which represents an annual dividend yield of 1.17%. See more information on Ipsen dividends here
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate is 6.07.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €6.02 in its last earnings report, beating expectations of €5.527. Following the earnings report the stock price went up 6.34%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in FR:IPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ipsen
Ipsen S.A. is an international biopharmaceutical enterprise, founded in 1929 and based in Boulogne-Billancourt, France. The company is dedicated to discovering, developing, and marketing innovative medicines globally, focusing on several key therapeutic areas: oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. Its extensive product lineup includes Somatuline, prescribed for neuroendocrine tumors and acromegaly; Decapeptyl, an agent for advanced metastatic prostate cancer; Cabometyx, addressing renal cell carcinoma and second-line hepatocellular carcinoma; and Onivyde, indicated for second-line metastatic pancreatic cancer. For neurological and aesthetic applications, Ipsen offers Dysport, used for motor muscular disorders and cosmetic purposes. The company also provides treatments for growth-related conditions, such as NutropinAq for growth failure in children (due to growth hormone deficiency, Turner syndrome, or chronic renal failure) and adults with growth hormone deficiency, along with Increlex for growth failure in pediatric and adolescent patients. In the realm of digestive health, Ipsen's offerings feature Smecta for both chronic and acute diarrhea, as well as pain associated with functional bowel diseases; Forlax for constipation; and Fortrans/Eziclen for bowel preparation before endoscopy, X-ray examinations, and colonic surgery. Other specialized products include Xermelo for carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device for symptomatic relief of gas-related gastrointestinal discomfort; and Etiasa for inflammatory bowel diseases. Furthermore, Tanakan is available for treating cognitive disorders in adults, vestibular vertigo, vestibular rehabilitation, and tinnitus. Ipsen's consumer healthcare division also markets various over-the-counter gastrointestinal remedies, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. To expand its research and market reach, Ipsen S.A. engages in strategic collaborations and alliances with numerous partners, such as Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure.
IPN Stock 12 Month Forecast
Average Price Target
€155.67
▼(-3.79% Downside)
Technical Analysis
Options Prices
Currently, No data available
---